[go: up one dir, main page]

UA103154C2 - Hla-a*1101-обмежений пептид wt1 і фармацевтична композиція, яка містить його - Google Patents

Hla-a*1101-обмежений пептид wt1 і фармацевтична композиція, яка містить його

Info

Publication number
UA103154C2
UA103154C2 UAA200907944A UAA200907944A UA103154C2 UA 103154 C2 UA103154 C2 UA 103154C2 UA A200907944 A UAA200907944 A UA A200907944A UA A200907944 A UAA200907944 A UA A200907944A UA 103154 C2 UA103154 C2 UA 103154C2
Authority
UA
Ukraine
Prior art keywords
amino acid
pharmaceutical composition
peptide
hla
restricted
Prior art date
Application number
UAA200907944A
Other languages
English (en)
Russian (ru)
Inventor
Харуо Сугіяма
Original Assignee
Інтернешнл Інстітьют Оф Кенсер Іммунолоджи, Інк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Інтернешнл Інстітьют Оф Кенсер Іммунолоджи, Інк. filed Critical Інтернешнл Інстітьют Оф Кенсер Іммунолоджи, Інк.
Publication of UA103154C2 publication Critical patent/UA103154C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)

Abstract

Винахід належить до пептиду, здатному зв'язуватися з молекулою HLA-A* 1101 і здатному індукувати цитотоксичний Т-лімфоцит (CTL), який складається з амінокислотної послідовності Thr Gly Val Lys Pro Phe Gin Cys Lys (SEQ ID NО:7), в якій від однієї амінокислоти до п'яти амінокислот можуть бути заміщені іншою (ими) амінокислотою (ами), а також до фармацевтичної композиції для лікування або профілактики злоякісного новоутворення, яка містить зазначений поліпептид, до способу індукції WT1-специфічного цитотоксичного Т-лімфоцита, набору, що містить зазначений поліпептид.
UAA200907944A 2006-12-28 2007-12-14 Hla-a*1101-обмежений пептид wt1 і фармацевтична композиція, яка містить його UA103154C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006355356 2006-12-28
PCT/JP2007/074146 WO2008081701A1 (ja) 2006-12-28 2007-12-14 Ｈｌａ－ａ＊１１０１拘束性ｗｔ１ペプチド、およびそれを含む医薬組成物

Publications (1)

Publication Number Publication Date
UA103154C2 true UA103154C2 (uk) 2013-09-25

Family

ID=39588385

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200907944A UA103154C2 (uk) 2006-12-28 2007-12-14 Hla-a*1101-обмежений пептид wt1 і фармацевтична композиція, яка містить його

Country Status (28)

Country Link
US (4) US8653038B2 (uk)
EP (6) EP2479275B1 (uk)
JP (1) JP5484734B2 (uk)
KR (1) KR101525261B1 (uk)
CN (5) CN102302788B (uk)
AR (1) AR064555A1 (uk)
AU (1) AU2007340679B2 (uk)
BR (1) BRPI0720988A2 (uk)
CA (5) CA2886622A1 (uk)
CY (1) CY1116011T1 (uk)
DK (3) DK2341142T3 (uk)
ES (4) ES2629578T3 (uk)
HK (3) HK1159686A1 (uk)
IL (4) IL199052A0 (uk)
MX (1) MX2009007008A (uk)
MY (1) MY161664A (uk)
NO (1) NO20092774L (uk)
NZ (4) NZ592509A (uk)
PH (1) PH12014500902B1 (uk)
PL (1) PL2341142T3 (uk)
PT (1) PT2341142E (uk)
RU (1) RU2481398C2 (uk)
SG (1) SG177222A1 (uk)
SI (1) SI2341142T1 (uk)
TW (3) TWI554280B (uk)
UA (1) UA103154C2 (uk)
WO (1) WO2008081701A1 (uk)
ZA (1) ZA200903633B (uk)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE540111T1 (de) 2003-11-05 2012-01-15 Int Inst Cancer Immunology Inc Hla-dr-bindendes antigenpeptid, das von wt1 abgeleitet ist
US8765687B2 (en) 2005-10-17 2014-07-01 Sloan Kettering Institute For Cancer Research WT1 HLA class II-binding peptides and compositions and methods comprising same
US9265816B2 (en) 2006-04-10 2016-02-23 Sloan Kettering Institute For Cancer Research Immunogenic WT-1 peptides and methods of use thereof
BRPI0808084A2 (pt) 2007-02-27 2014-07-22 Int Inst Cancer Immunology Inc Método para ativação de células t auxiliadoras e composição para uso no método.
AR083295A1 (es) 2010-10-05 2013-02-13 Univ Osaka Metodo para activar celulas t auxiliares
PE20141271A1 (es) * 2011-04-01 2014-10-08 Sloan Kettering Inst Cancer Anticuerpos tipo receptor de celulas t especificos para un peptido wt1 presentado por hla-a2
JP6122779B2 (ja) * 2011-09-14 2017-04-26 株式会社癌免疫研究所 抗ｗｔ１抗体の測定方法
CN104684577B (zh) 2012-01-13 2018-05-08 纪念斯隆凯特林癌症中心 免疫原性wt-1肽及其使用方法
CA2884366A1 (en) 2012-09-12 2014-03-20 International Institute Of Cancer Immunology, Inc. Antigen-specific helper t-cell receptor genes
EP3640375A3 (en) 2012-12-11 2020-07-29 Albert Einstein College of Medicine Methods for high throughput receptor/ligand identification
KR102158225B1 (ko) 2012-12-17 2020-09-21 오츠카 세이야쿠 가부시키가이샤 헬퍼 t세포의 활성화 방법
EP3769782A1 (en) 2013-01-15 2021-01-27 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
JP6512567B2 (ja) 2013-02-05 2019-05-15 日東電工株式会社 経皮投与用ｗｔ１ペプチド癌ワクチン組成物
CN103961307B (zh) 2013-02-05 2019-11-29 日东电工株式会社 经皮给予用wt1肽癌症疫苗组合物
CA2841014A1 (en) 2013-02-05 2014-08-05 Nitto Denko Corporation Tape preparation of wt1 peptide cancer vaccine for transdermal administration
US20140234377A1 (en) 2013-02-05 2014-08-21 Nitto Denko Corporation Vaccine composition for mucosal administration
KR20140100422A (ko) 2013-02-05 2014-08-14 닛토덴코 가부시키가이샤 백신 조성물
CA2840988A1 (en) 2013-02-05 2014-08-05 Nitto Denko Corporation Wt1 peptide cancer vaccine composition for mucosal administration
JP6440360B2 (ja) 2013-02-05 2018-12-19 日東電工株式会社 経皮投与用ワクチン組成物
CA2840954A1 (en) 2013-02-05 2014-08-05 Nitto Denko Corporation Vaccine composition for transdermal or mucosal administration
JP6671956B2 (ja) * 2013-03-29 2020-03-25 大日本住友製薬株式会社 Ｅｒａｐ１によるトリミング機能をきっかけとしたコンジュゲートワクチン
SG11201507883SA (en) * 2013-03-29 2015-10-29 Sumitomo Dainippon Pharma Co Ltd Wt1-antigen peptide conjugate vaccine
MX2017007595A (es) 2014-12-11 2018-03-01 Int Inst Cancer Immunology Inc Inmunoterapia para enfermedad angiogenica.
KR20190044029A (ko) 2016-05-18 2019-04-29 알버트 아인슈타인 컬리지 오브 메디슨, 인크. 변이체 pd-l1 폴리펩타이드, t-세포 조절 다량체 폴리펩타이드 및 이들의 사용 방법
BR112018073606A2 (pt) 2016-05-18 2019-02-26 Cue Biopharma, Inc. polipeptídeos multiméricos moduladores de células t e métodos de uso dos mesmos
PL3558339T3 (pl) 2016-12-22 2024-08-05 Cue Biopharma, Inc. Multimeryczne polipeptydy modulujące limfocyty t i sposoby ich stosowania
US11851471B2 (en) 2017-01-09 2023-12-26 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
IL269000B2 (en) 2017-03-15 2024-06-01 Cue Biopharma Inc Methods for modulating an immune response
WO2019131722A1 (ja) * 2017-12-27 2019-07-04 大日本住友製薬株式会社 Ｗｔ１由来ペプチドのコンジュゲート体およびこれを含む組成物
EP3737689A4 (en) 2018-01-09 2021-12-01 Cue Biopharma, Inc. MULTIMER POLYPEPTIDES T-LYMPHOCYTE MODULATORS AND THEIR METHODS OF USE
CN111919303B (zh) 2018-03-29 2023-08-29 罗姆股份有限公司 半导体装置
CN116096405A (zh) 2020-05-12 2023-05-09 Cue生物制药股份有限公司 多聚体t细胞调节多肽及其使用方法
EP4151227A4 (en) * 2020-05-12 2025-01-15 Sumitomo Pharma Co Ltd PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCER
JP2023541366A (ja) 2020-09-09 2023-10-02 キュー バイオファーマ， インコーポレイテッド １型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節多量体ポリペプチド及びその使用方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4575374A (en) * 1983-02-16 1986-03-11 Anis Aziz Y Flexible anterior chamber lens
US5763209A (en) 1988-09-26 1998-06-09 Arch Development Corporation Methods and materials relating to the functional domains of DNA binding proteins
US5584304A (en) * 1993-11-18 1996-12-17 Allergan, Inc. Method of inserting an IOL using a forceps inside a folding tube
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5984962A (en) * 1996-01-22 1999-11-16 Quantum Vision, Inc. Adjustable intraocular lens
US6207375B1 (en) * 1996-12-11 2001-03-27 Mayo Foundation For Medical Educational & Research TGF-β inducible early factor-1 (TIEF-1) and a method to detect breast cancer
US20030039635A1 (en) * 1998-09-30 2003-02-27 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7063854B1 (en) * 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
US7115272B1 (en) * 1998-09-30 2006-10-03 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030072767A1 (en) * 1998-09-30 2003-04-17 Alexander Gaiger Compositions and methods for WT1 specific immunotherapy
MXPA01003344A (es) * 1998-09-30 2004-04-21 Corixa Corp Composiciones y metodos para inmunoterapia especifica de wt1.
US7144581B2 (en) * 2000-10-09 2006-12-05 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7655249B2 (en) * 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7901693B2 (en) * 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
EP1169347B1 (en) * 1999-04-02 2008-07-02 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
WO2001025273A2 (en) * 1999-10-04 2001-04-12 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
US20030082194A1 (en) * 2000-02-22 2003-05-01 Alexander Gaiger Compositions and methods for diagnosis and therapy of malignant mesothelioma
WO2001062920A2 (en) 2000-02-22 2001-08-30 Corixa Corporation Compositions and methods for diagnosis and therapy of malignant mesothelioma
CN1281625C (zh) * 2001-03-22 2006-10-25 株式会社癌免疫研究所 经修饰的wt1肽
IL145015A0 (en) * 2001-08-21 2002-06-30 Nun Yehoshua Ben Accommodating lens
US7553494B2 (en) * 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
WO2003106682A1 (ja) * 2002-06-12 2003-12-24 中外製薬株式会社 Ｈｌａ−ａ２４拘束性癌抗原ペプチド
BR0311784A (pt) * 2002-06-14 2005-03-08 Merck & Co Inc Composto, composição farmacêutica, métodos de tratar ou prevenir o câncer, de modular a formação do fuso mitótico e de inibir a cinesina mitótica e processo para fabricar uma composição farmacêutica
SE0201863D0 (en) * 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
EP2154145B1 (en) 2003-01-15 2013-04-24 International Institute of Cancer Immunology, Inc. Dimerized peptide
US7976520B2 (en) * 2004-01-12 2011-07-12 Nulens Ltd. Eye wall anchored fixtures
SI1731605T1 (sl) * 2004-03-31 2010-07-30 Internat Inst Of Cancer Immunolog Inc Peptidi antigena karcinoma izvedeni iz WT1
JP2006045287A (ja) 2004-08-02 2006-02-16 Inax Corp 弾性接着剤及びタイル張り壁面
JP4719876B2 (ja) * 2005-04-04 2011-07-06 国立大学法人愛媛大学 Ｈｌａクラスｉｉ拘束性ｗｔ１抗原ペプチド
WO2010037395A2 (en) * 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring

Also Published As

Publication number Publication date
TW200835513A (en) 2008-09-01
AR064555A1 (es) 2009-04-08
NZ592510A (en) 2012-11-30
DK2479275T3 (en) 2015-12-14
US8653038B2 (en) 2014-02-18
US20180064795A1 (en) 2018-03-08
EP2980219B1 (en) 2018-11-14
CN102659924A (zh) 2012-09-12
ES2556831T3 (es) 2016-01-20
ZA200903633B (en) 2010-02-24
PH12014500902B1 (en) 2018-08-10
DK2479276T3 (en) 2015-12-21
CA2670658A1 (en) 2008-07-10
EP2479275B1 (en) 2015-10-28
JPWO2008081701A1 (ja) 2010-04-30
EP2479275A1 (en) 2012-07-25
NZ577443A (en) 2011-12-22
EP2341142A2 (en) 2011-07-06
PL2341142T3 (pl) 2015-04-30
AU2007340679B2 (en) 2013-09-12
BRPI0720988A2 (pt) 2014-03-18
TW201630620A (zh) 2016-09-01
CN102335439A (zh) 2012-02-01
TWI554280B (zh) 2016-10-21
CA2886621A1 (en) 2008-07-10
CN102302788B (zh) 2016-06-15
HK1221252A1 (zh) 2017-05-26
US9272026B2 (en) 2016-03-01
RU2481398C2 (ru) 2013-05-10
TW201345544A (zh) 2013-11-16
EP2341142A3 (en) 2011-09-07
CA2886619A1 (en) 2008-07-10
NO20092774L (no) 2009-07-27
TWI417103B (zh) 2013-12-01
WO2008081701A1 (ja) 2008-07-10
CA2886620A1 (en) 2008-07-10
PT2341142E (pt) 2015-02-13
EP3026115A1 (en) 2016-06-01
EP2098595A1 (en) 2009-09-09
US20110098233A1 (en) 2011-04-28
CN102302788A (zh) 2012-01-04
SG177222A1 (en) 2012-01-30
ES2554775T3 (es) 2015-12-23
NZ592509A (en) 2012-11-30
MX2009007008A (es) 2009-07-10
EP3026115B1 (en) 2017-05-17
RU2009128979A (ru) 2011-02-10
SI2341142T1 (sl) 2015-03-31
EP2098595A4 (en) 2010-03-17
NZ601175A (en) 2012-12-21
KR101525261B1 (ko) 2015-06-02
EP2341142B1 (en) 2014-11-26
AU2007340679A1 (en) 2008-07-10
HK1159686A1 (en) 2012-08-03
CA2886622A1 (en) 2008-07-10
PH12014500902A1 (en) 2016-01-11
ES2526425T3 (es) 2015-01-12
US20140134200A1 (en) 2014-05-15
IL199052A0 (en) 2010-03-28
CN101573448A (zh) 2009-11-04
CN102659924B (zh) 2015-11-25
EP2980219A1 (en) 2016-02-03
CN102295682A (zh) 2011-12-28
EP2479276A1 (en) 2012-07-25
HK1173187A1 (zh) 2013-05-10
ES2629578T3 (es) 2017-08-11
EP2341142B8 (en) 2015-01-14
EP2479276B1 (en) 2015-12-09
IL215334A0 (en) 2011-11-30
IL215333A0 (en) 2011-11-30
JP5484734B2 (ja) 2014-05-07
CN102335439B (zh) 2015-04-22
TWI599367B (zh) 2017-09-21
CN101573448B (zh) 2012-07-11
MY161664A (en) 2017-04-28
KR20090102772A (ko) 2009-09-30
IL215332A0 (en) 2011-11-30
CY1116011T1 (el) 2017-01-25
DK2341142T3 (en) 2014-12-08
US20160199472A1 (en) 2016-07-14

Similar Documents

Publication Publication Date Title
UA103154C2 (uk) Hla-a*1101-обмежений пептид wt1 і фармацевтична композиція, яка містить його
ATE527353T1 (de) Pdgf-bindendes polypeptid aus protein a
MX2008009493A (es) Peptido novedoso y uso del mismo.
TWI653980B (zh) 治療及預防缺血性傷害之組成物與方法
ATE442381T1 (de) Nukleotid- und proteinsequenzen eines serrate- gens aus wirbeltieren und darauf basierende verfahren
NZ591130A (en) Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof
JP2013543497A5 (uk)
JP2013518115A5 (uk)
WO2005116051A3 (de) An mhc-moleküle bindende tumor-assoziierte peptide
AR036196A1 (es) Agentes de contraste multimericos dirigidos a base de peptidos
MX2020010806A (es) Peptidos anti-inflamatorios y usos de los mismos.
JP2002530430A (ja) Ｃ型肝炎ウイルスｎｓ３プロテアーゼ阻害用の医薬組成物
PT2213680E (pt) Péptidos que possuem uma atividade farmacológica para o tratamento de distúrbios associados à migração de células alteradas, tais como o cancro
EP1801206A4 (en) METHOD OF SYNTHESIZING L-ARGININE, L-ORNITHINE, OR L-CITRULLINE
MX2009010965A (es) Péptidos de tem8 y vacunas que los contienen.
DE602004001727D1 (de) Verfahren zur herstellung cyclischer peptide
RU2015103816A (ru) ПРОНИКАЮЩИЕ В КЛЕТКУ ПЕПТИДЫ, МИШЕНЬЮ КОТОРЫХ ЯВЛЯЕТСЯ eIF4E
CY1109631T1 (el) Χρησιμοποιηση πεπτιδιων, τα οποια εχουν παραχθει απο την αα- ή ββ-αλυσιδα του ανθρωπινου ινωδογονου, για τη θεραπεια σοκ
EA201100459A1 (ru) Композиции, включающие интерлейкин-1 и пептиды
WO2008047370A3 (en) Compositions and methods for inducing angiogenesis
RU2007115411A (ru) Пептиды hsp60 и их apl-производные и фармацевтические композиции
US20220340629A1 (en) Myosin Derived Peptides and Related Compounds with Anticoagulant Activities
EP1765851A4 (en) OPTICAL CHEMO AND BIOSENSORS BASED ON A PLANAR RESONATOR
JP2005126360A (ja) 新規なポリペプチドで構成されたコラゲナーゼ阻害剤
NZ593086A (en) Isolated peptide binding to human leukocyte antigen (HLA) and having cytotoxic T lymphocyte (CTL) inducibility